Alnylam Pharmaceuticals (ALNY) Receives “Neutral” Rating from Goldman Sachs Group

Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating reissued by equities research analysts at Goldman Sachs Group in a research note issued to investors on Thursday, MarketBeat.com reports. They presently have a $80.00 price objective on the biopharmaceutical company’s stock. Goldman Sachs Group’s price target would suggest a potential upside of 16.06% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. Cantor Fitzgerald restated a “buy” rating and issued a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, April 9th. Leerink Swann upped their price objective on Alnylam Pharmaceuticals to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 9th. BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $119.00 to $126.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. Finally, Evercore ISI initiated coverage on Alnylam Pharmaceuticals in a research report on Thursday, April 11th. They issued an “outperform” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $127.44.

Shares of NASDAQ:ALNY opened at $68.93 on Thursday. Alnylam Pharmaceuticals has a twelve month low of $60.27 and a twelve month high of $124.21. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. The company has a market capitalization of $7.34 billion, a P/E ratio of -9.11 and a beta of 2.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. During the same quarter in the prior year, the company earned ($1.22) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 52.0% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals will post -8.48 earnings per share for the current year.

In other news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the transaction, the director now owns 250,633 shares in the company, valued at approximately $22,113,349.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Maraganore sold 49,457 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total value of $3,461,990.00. Following the transaction, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. FMR LLC lifted its position in shares of Alnylam Pharmaceuticals by 5.2% during the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock valued at $1,490,122,000 after buying an additional 791,113 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Alnylam Pharmaceuticals by 5.4% during the 1st quarter. Wellington Management Group LLP now owns 14,832,598 shares of the biopharmaceutical company’s stock valued at $1,386,107,000 after buying an additional 766,371 shares in the last quarter. Vanguard Group Inc lifted its position in shares of Alnylam Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc now owns 7,605,253 shares of the biopharmaceutical company’s stock valued at $665,612,000 after buying an additional 66,740 shares in the last quarter. BlackRock Inc. lifted its position in shares of Alnylam Pharmaceuticals by 4.6% during the 1st quarter. BlackRock Inc. now owns 6,428,127 shares of the biopharmaceutical company’s stock valued at $600,707,000 after buying an additional 282,322 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of Alnylam Pharmaceuticals by 19.8% during the 1st quarter. Baillie Gifford & Co. now owns 5,684,504 shares of the biopharmaceutical company’s stock valued at $531,217,000 after buying an additional 937,654 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Further Reading: Commodities

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QUALCOMM, Inc.  Shares Sold by Fmr LLC
QUALCOMM, Inc. Shares Sold by Fmr LLC
Chevron Co.  Stake Decreased by Fmr LLC
Chevron Co. Stake Decreased by Fmr LLC
Abbott Laboratories  Holdings Lifted by WealthPLAN Partners LLC
Abbott Laboratories Holdings Lifted by WealthPLAN Partners LLC
SPDR Portfolio Large Cap ETF  Shares Bought by WealthPLAN Partners LLC
SPDR Portfolio Large Cap ETF Shares Bought by WealthPLAN Partners LLC
WealthPLAN Partners LLC Has $3.98 Million Stake in Medtronic PLC
WealthPLAN Partners LLC Has $3.98 Million Stake in Medtronic PLC
EVOS  One Day Trading Volume Hits $42.00
EVOS One Day Trading Volume Hits $42.00


 
© 2006-2019 Zolmax.